In a phase 2 study, iptacopan — an oral, highly potent proximal complement inhibitor — reduced proteinuria in patients with IgA nephropathy. New research findings from a phase 3 trial are ...

Climb Bio believes CLYM116 is a potential best-in-class approach to address significant unmet need in patients with IgA nephropathy and other B-cell mediated diseases. This transaction furthers ...

Climb Bio believes CLYM116 is a potential best-in-class approach to address significant unmet need in patients with IgA nephropathy and other B-cell mediated diseases. This transaction furthers Climb ...